0 311

Cited 3 times in

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.

DC FieldValueLanguage
dc.contributor.author김현기-
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.contributor.author윤미진-
dc.contributor.author정민규-
dc.contributor.author정현철-
dc.contributor.author조응혁-
dc.contributor.author형우진-
dc.contributor.author정재호-
dc.contributor.author김형일-
dc.contributor.author김효송-
dc.date.accessioned2017-02-27T08:27:30Z-
dc.date.available2017-02-27T08:27:30Z-
dc.date.issued2016-
dc.identifier.issn0914-7187-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147188-
dc.description.abstractOBJECTIVE: Gastric neuroendocrine carcinomas (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are very rare, aggressive tumors of the stomach. We aimed to examine predictive role of pretreatment (18)F-FDG PET/CT-assessed metabolic parameter of primary tumors and metastases in patients with gastric NEC and MANEC. METHODS: We conducted a review of the 27 patients with histopathologically confirmed NECs (n = 10) and MANEC (n = 17) of the stomach at our institution between January 2005 and December 2012. All patients underwent (18)F-FDG-PET examination at diagnosis. Metabolic parameters [SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] of the primary tumor and metastases on baseline PET/CT were analyzed. RESULTS: The median follow-up duration was 39.4 months (95 % CI 20.0-58.1 months) and the median overall survival (OS) was 25.7 months (95 % CI 14.1-37.2 months). All gastric lesions were well visualized (average SUVmax = 12.0, range 3.0-41.8). When subjects were divided into two groups by ROC cut-off value of 210.9 and 612, patients with high TLG in primary lesion and metastases showed poorer prognosis compared to low TLG patients (P = 0.09, P = 0.002, respectively). In the sub-analysis of patients with metastasis (n = 12), patients with high TLG in whole body tumor showed significantly shorter OS compared to those with low TLG (31.7 ± 11.4 vs. 7.2 ± 2.1 months, P = 0.006). CONCLUSION: (18)F-FDG PET/CT is useful in evaluating prognosis of advanced gastric cancer with neuroendocrine carcinoma components. Baseline MTV of primary gastric cancer with metastatic disease, and MTV, TLG of metastases may be prognostic markers in patients with gastric NEC and MANEC.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent279~286-
dc.publisherSpringer Japan-
dc.relation.isPartOfANNALS OF NUCLEAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/diagnostic imaging*-
dc.subject.MESHAdenocarcinoma/metabolism-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCarcinoma, Neuroendocrine/diagnostic imaging*-
dc.subject.MESHCarcinoma, Neuroendocrine/metabolism-
dc.subject.MESHCarcinoma, Neuroendocrine/pathology-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHPositron Emission Tomography Computed Tomography*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHStomach Neoplasms/diagnostic imaging*-
dc.subject.MESHStomach Neoplasms/metabolism-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHSurvival Analysis-
dc.titlePrognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.-
dc.typeArticle-
dc.publisher.locationJapan-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pathology-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorHyunki Kim-
dc.contributor.googleauthorBeodeul Kang-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorWoo Jin Hyung-
dc.contributor.googleauthorJae-Ho Cheong-
dc.contributor.googleauthorHyoung-Il Kim-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorMijin Yun-
dc.contributor.googleauthorArthur Cho-
dc.contributor.googleauthorMinkyu Jung-
dc.identifier.doi10.1007/s12149-016-1059-x-
dc.contributor.localIdA01108-
dc.contributor.localIdA01281-
dc.contributor.localIdA01316-
dc.contributor.localIdA02550-
dc.contributor.localIdA03606-
dc.contributor.localIdA03773-
dc.contributor.localIdA03887-
dc.contributor.localIdA04382-
dc.contributor.localIdA03717-
dc.contributor.localIdA01154-
dc.contributor.localIdA01202-
dc.relation.journalcodeJ00167-
dc.identifier.eissn1864-6433-
dc.identifier.pmid26837515-
dc.identifier.urlhttp://link.springer.com/article/10.1007/s12149-016-1059-x-
dc.subject.keyword18F-FDG PET/CT-
dc.subject.keywordGastric-
dc.subject.keywordMixed adenoneuroendocine carcinoma-
dc.subject.keywordNeuroendocrine carcinoma-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKim, Hyun Ki-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameYun, Mi Jin-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameCho, Arthur Eung Hyuck-
dc.contributor.alternativeNameHyung, Woo Jin-
dc.contributor.alternativeNameCheong, Jae Ho-
dc.contributor.alternativeNameKim, Hyoung Il-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.affiliatedAuthorKim, Hyun Ki-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.contributor.affiliatedAuthorYun, Mi Jin-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorCho, Arthur Eung Hyuck-
dc.contributor.affiliatedAuthorHyung, Woo Jin-
dc.contributor.affiliatedAuthorCheong, Jae Ho-
dc.contributor.affiliatedAuthorKim, Hyoung Il-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.citation.volume30-
dc.citation.number4-
dc.citation.startPage279-
dc.citation.endPage286-
dc.identifier.bibliographicCitationANNALS OF NUCLEAR MEDICINE, Vol.30(4) : 279-286, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.